MIMS Education

Implementing in-hospital initiation of SGLT2 inhibitors in clinical practice

Implementing in-hospital initiation of SGLT2 inhibitors in clinical practice

CardiologyEmergency MedicineGeneral Practice
A badge with ribbon in color black CME Unit:1 Point | An analog clock in color black 50 minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 30 Sep 2024 

Overview

About this course

Despite improvements in the management of heart failure (HF), patients still face a significant risk of mortality and rehospitalisation following admission for acute HF. Congestion remains the primary cause of hospitalisation for patients with acute decompensated HF; each episode of HF decompensation can result in organ damage and have long-term consequences on patient outcomes. However, hospitalisation for HF presents an opportunity to adjust pharmacotherapy, making the in-hospital and early post-discharge periods an ideal time to initiate and optimise HF therapies, thus potentially improving patient outcomes – both immediately after discharge and in the long term.

In this presentation, Professor Christianne discusses the evidence supporting early in-hospital initiation and up-titration of guideline-directed medical therapy (GDMT) for patients with HF. Specifically, she explains the benefits of adding sodium-glucose cotransporter-2 (SGLT2) inhibitors for this patient group.

Learning outcomes

Upon completion of this module, participants will be able to:
  • Understand the pathophysiological aspects of acute HF versus chronic HF.
  • Discuss evidence supporting in-hospital initiation and up-titration of GDMT.
  • Explain the advantages of early initiation of SGLT2 inhibitors in clinical practice.
  • Identify patients who would benefit from early initiation of SGLT2 inhibitors.

Topics covered

  • Acute HF versus chronic heart failure.
  • Effects of acute HF (mortality rate, hospitalisation rate, organ damage and rehospitalisation rate).
  • Benefit of early intervention with GDMT including SGLT2 inhibitor after acute decompensation as demonstrated in pivotal trials:
    • PIONEER-HF
    • SOLOIST-WHF
    • STRONG-HF
    • EMPULSE
  • Case presentation of patients with heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) including recommendations from the latest European Society of Cardiology (ESC) guidelines and expert consensus.

Topics covered

  • PIONEER-HF
  • SOLOIST-WHF
  • STRONG-HF
  • EMPULSE

1 CME Point Available

  • This module is accredited for 1 CME Point for medical practitioners enrolled in The Medical Council of Hong Kong’s Continuing Medical Education Programme for Practising Doctors who are not taking CME for Specialists.
    • This module is accredited for both Hong Kong Academy of Medicine (HKAM) members and non-members.
  • This module is accredited for 1 CME Point for fellows of the Hong Kong College of Emergency Medicine, Hong Kong College of Community Medicine, Hong Kong College of Physicians, The Hong Kong College of Anaesthesiologists, and The Hong Kong College of Pathologists.
  • Please note that this module will not earn CME credit for fellows of colleges not listed here.
  • A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.